Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories announces the launch of Vigabatrin Tablets, USP in the U.S. Market."
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | APARNA TEKURI aparnatekuri@drreddys.com (Ph: +91-40- 49002446) |
Reddy's Laboratories announces the launch of
Tablets, USP in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. February 2, 2021-
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together
referred to as "Dr. Reddy's") today announced the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent
generic version of Sabril (vigabatrin) Tablets, USP, approved by the U.S. Food and Drug Administration (USFDA).
"We are pleased that this product has been designated
as a Competitive Generic Therapy (CGT) by the FDA," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr.
Reddy's Laboratories. "With a CGT designation, we have 180-day CGT exclusivity to market this product."
The Sabril brand and generic had U.S. sales of approximately
$141 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.
Dr. Reddy's Vigabatrin Tablets, USP are available in 500
mg tablets in a bottle count size of 100.
Please see for full prescribing information including boxed
Sabril is a trademark of Lundbeck.
*IMS National Sales Perspective: Retail and Non-Retail MAT December
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients,
Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs,
custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets
across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the management's current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation,
(i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest
rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii)
changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central
banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and
(vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic
downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19),
and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including
those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form
20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."